Novel biomarker-targeted drugs fail to cut heart attacks, strokes in trials

Recent clinical trials of drugs targeting hsCRP and Lp(a) failed to reduce cardiovascular events, reinforcing that lifestyle interventions remain the most evidence-based approach. The findings challenge the precision-medicine paradigm for cardiovascular risk reduction and may shift research priorities.